

Short Communication

Essential oils for COVID-19 management: A systematic review of randomized controlled trials

Teuku F. Duta^{1*}, Diva R. Rizki¹, Agnia Purnama², Marius Rademaker³, Uwe Wollina⁴, Yogesh Acharya⁵, Ziad Abdeen⁶, Sandro GV. Rosa⁷, Henning B. Nielsen^{8,9} and Kannan Subbaram¹⁰

¹Medical Research Unit, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia; ²Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Syiah Kuala, Banda Aceh, Indonesia; ³Clinical Trial New Zealand, Waikato Hospital Campus, Hamilton, New Zealand; ⁴Department of Dermatology and Allergology, Städtisches Klinikum Dresden, Academic Teaching Hospital, Dresden, Germany; ⁵Western Vascular Institute, Galway University Hospital, Galway, Ireland; ⁶Department of Community Health, Faculty of Medicine, Al-Quds University, East Jerusalem, Palestine; ⁷Division of Pharmacy, National Institute of Industrial Property, Rio de Janeiro, Brazil; ⁸Department of Anesthesia and Intensive Care, Zealand University Hospital Roskilde, Roskilde, Denmark; ⁹Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Denmark; ¹⁰School of Medicine, The Maldives National University, Maldives.

*Corresponding author: faisduta@gmail.com

Abstract

Essential oils can be a beneficial adjuvant therapy in managing coronavirus disease 2019 (COVID-19). This systematic review aims to evaluate the efficacy of essential oils in ameliorative COVID-19-related symptoms. Published studies reporting the efficacy of essential oils as adjuvant therapy for COVID-19 were screened on Scilit, Scopus, SciFinder, and PubMed (December 7th, 2022). Inclusion criteria include the randomized controlled trials (RCTs) participated by those diagnosed with COVID-19 and treated with essential oils as adjuvant therapy. Quality assessment was carried out using Cochrane 'risk-of-bias' 2.0 tool. A total of 2112 records were retrieved from the initial screening, which was reduced to four publications ($n=344$ individuals). The foregoing studies reported that essential oils could improve the recovery rate, alleviate post-COVID-19 fatigue, and prevent disease progression. Regarding their potential antiviral activity, better designed studies are needed. In conclusion, essential oils as adjuvant therapy are beneficial in ameliorating mild COVID-19 symptoms.

Keywords: Volatile compound, aromatherapy, COVID-19, SARS-CoV-2 infection, respiratory tract infection

Introduction

Coronavirus disease 2019 (COVID-19) has been a major concern for global health issues [1]. As of April 5th, 2023, the number of deaths from the COVID-19 pandemic has reached 6,893,190 worldwide with a total of 762,201,169 infection cases [2]. This disease is caused by a positive-sense single-stranded RNA virus – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [3]. Patients suffering from COVID-19 may experience mild symptoms including fever, cough, headache, and sputum which can progress to more severe conditions including acute respiratory distress syndrome (ARDS) and death [4]. The available antivirals such as remdesivir, nirmatrelvir, and molnupiravir have some benefit in reducing hospitalization and death, but real-world studies suggest a lower efficacy of these drugs over that claimed in the original trials [5,6].

Previously, researchers have explored the utility of essential oils as antiviral, including against human immunodeficiency virus (HIV) [7] and Middle East respiratory syndrome



coronavirus (MERS-CoV) [8]. There is some evidence that essential oils can improve flu symptoms such as fatigue, sputum, fever, and cough [9-12]. Review articles have suggested that essential oils could also be used in managing COVID-19 disease [13,14]. Several clinical studies have been performed to test the efficacy of essential oils in improving COVID-19-related symptoms [15-17]. Unfortunately, previously published systematic reviews only covered computational or preclinical studies [18,19]. Herein, we performed a systematic review of randomized controlled trials assessing the efficacy of essential oils in COVID-19 management.

Methods

Search strategies

The literature search, screening, and selection process followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), which was performed independently by two reviewers – D.R.R. and A.P. The search was performed on December 7th, 2022, on Scilit, Scopus, SciFinder, and PubMed without restriction on the publication date. The truncation of “essential oils to treat COVID-19” was used, where Boolean operators (‘AND’ and ‘OR’) were applied. To be included, the enrolled participants must be infected by SARS-CoV-2 (proven by RT-PCR) or had post-infection symptoms. Studies reported the results of essential oil therapy as adjuvant to standard care were included. Those using unclear compositions of essential oils were not included. Only randomized controlled trials (RCTs) reported in English were included. Review articles, case reports, conference abstracts, patents, commentaries, editorials, and erratum were excluded.

Quality assessment

The quality of the included studies was evaluated by using RoB 2.0: A revised Cochrane risk-of-bias tool for randomized trials, performed by D.R.R. and A.P. independently. The assessment tool has 5 domains, which are: (1) Randomization process; (2) Deviation from intended intervention; (3) Missing outcome data; (4) Measurement of the outcome; and (5) Selection of the reported result. Each domain was marked as ‘low risk’, ‘some concerns’, or ‘high risk’ as the quality indicator.

Data extraction

Number of total participants, age range, and COVID-19 severity were collected as participants’ characteristics. We also collected the names of essential oils and their administration method. Outcomes such as viral clearance, symptoms recovery, fatigue level, and adverse effects were recorded. Most of the data were presented narratively, hence no data conversion was applied.

Results

Characteristics of included studies

A total of 2,112 studies were initially identified. By applying the inclusion and exclusion criteria, we obtained 4 studies; two from India, one from the United States, and one from Malaysia. The flow diagram summarizing the selection process is presented in **Figure 1**. During selection, a study performed on healthcare workers who were not infected by SARS-CoV-2 was considered irrelevant, hence being excluded [21]. Studies from Malaysia and India were also excluded because they used essential oils-containing mouthwash but did not specify the essential oils [22-24]. A total of 344 participants were included. Except for Dutt *et al.* [15] and Khairiah *et al.* [20], the other 2 studies included a placebo-controlled group [16,17]. The four studies used mixtures of essential oils as an adjunct therapy for symptomatic COVID-19 [15,17] or post-COVID-19 [16]. Details of the characteristics of the included studies are presented in **Table 1**.

Efficacy of essential oil in managing COVID-19

Essential oils were reported to reduce both symptoms of COVID-19 disease [15,17,20] and sequelae [16]. The administration of essential oils as adjuvant could be observed to be more beneficial for mild COVID-19 as compared to moderate severity [15,17]. Improvement in anosmia

and dysgeusia was particularly observed in two study [17,20]. However, it is still unclear whether the essential oils could be more beneficial in accelerating viral clearance as compared to the standard care [15,17]. These differences in efficacy could be derived from the heterogenous composition of the essential oils used. Studies have used mixtures of 17–19 different essential oils [15,17]. Among those components, the most commonly used essential oils were eucalyptus, lemon oil, thyme oil, clove oil, and frankincense oil. Routes of administration varied; oral [15] and respiratory [16,17,20]. Regardless, these studies reported no adverse events that could be correlated with essential oils administration, suggesting their safety as therapeutic agents.




Figure 1. PRISMA flow-chart of the included studies that reported on therapeutic effect of essential oils against COVID-19.

Quality of the included studies

Results from the quality assessment have been presented in **Figure 2**. The included studies were considered to have moderate to high qualities. Among the included studies, two studies were marked with a low risk of bias [16,17] and two studies – some concerns of bias [15,20]. The studies by Dutt *et al.* [15] and Khairiah *et al.* [20] had some concerns due to not clearly stating how the blinding was conducted, especially with routine examinations performed during the study. The rest of the other domains were considered as low risk of bias.

Study	Risk of bias domains					Overall
	D1	D2	D3	D4	D5	
Dutt, et al., 2021	+	+	+	-	+	-
Hawkins, et al., 2022	+	+	+	+	+	+
Rathod, et al., 2022	+	+	+	+	+	+
Khairiah, et al., 2022	+	+	+	-	+	-

Domains:
D1: Bias arising from the randomization process.
D2: Bias due to deviations from intended intervention.
D3: Bias due to missing outcome data.
D4: Bias in measurement of the outcome.
D5: Bias in selection of the reported result.

Judgement
- Some concerns
+ Low

Figure 2. Results from the quality assessment using Cochrane 'risk-of-bias' tool.

Table 1. Characteristics and outcomes of the included studies

Author, year (ref)	Country	Participants	Essential oils	Administration	Outcome
Dutt <i>et al.</i> 2021 [15]	India	n=60 Age: ≥18 years Severity: Mild to moderate symptoms	Oregano, clove, lemongrass, cinnamon, neem, blackseed, spearmint, peppermint, frankincense, lemon, eucalyptus, coriander oil, lavender, rosemary, thyme, tea tree, and sweet orange	Oral	<ul style="list-style-type: none"> • Rapid viral clearance • Symptomatic recovery • Safe based on serum ferritin, CRP, and NLR
Hawkins <i>et al.</i> 2022 [16]	United States	n=40 (female only) Age: 19–49 years 5–6 months post-COVID-19	Thyme, orange peel, clove, and frankincense	Inhalation	<ul style="list-style-type: none"> • Lowering fatigue • Headache mostly from post-COVID-19 symptoms
Rathod <i>et al.</i> 2022 [17]	India	Phase I n=45 Age: 18–55 years Phase II n=99 Aged: 18–65 years Severity: Asymptomatic or mild	Lemon, oregano, tea tree, java citronella, turmeric, peppermint, lavender, ginger, frankincense, eucalyptus, wheat germ, basil, cedarwood, holy basil, cinnamon, sage, and clove	Nebulization	<ul style="list-style-type: none"> • Reduced the severity progression • Ameliorate anosmia and dysgeusia • Did not affect the viral clearance
Khairiah <i>et al.</i> 2022 [20]	Malaysia	n=100 Aged: ≥18 years Severity: Mild to moderate symptoms	Eucalyptus, lemon	Inhalation	<ul style="list-style-type: none"> • Reduce the severity and number of symptoms • No adverse event

CRP: C-Reactive Protein; NLR: Neutrophil Lymphocyte Ratio

Discussion

Administration of essential oils has been found efficacious in preventing both disease progression and better symptomatic recovery after COVID-19 disease [15,17,20]. Faster viral clearance could be attributed to the antiviral activities of essential oils that have been observed for eucalyptus oil, rosemary oil [25-27], lemon oil, and geranium oil [28]. Some antiviral activities involve the downregulation of angiotensin-converting enzyme II (ACE2) and transmembrane protease serine 2 (TMPRSS2) which act as viral entry points [29]. Several antiviral mechanisms of essential oils have been suggested (**Figure 3**) [19]. The present studies were not able to draw a clear conclusion regarding the antiviral activities of essential oils. Previous studies have suggested that only some essential oils have antiviral activities, and there remains the possibility that other essential oils may actually facilitate viral entry [28,30].

Though the evidence for an antiviral effect of essential oils is unclear, their efficacy in improving COVID-19 symptoms is better [15,17] including the sequelae of COVID-19 [16]. Patients with COVID-19 disease can develop severe symptoms secondary to the unregulated release of proinflammatory cytokines such as interleukin(IL)-6, IL-7, as well as tumor necrosis factor- α (TNF- α) [31,32]. The long-term impacts of COVID-19 are derived from the alteration of neurotransmitter signaling concomitant to dysregulation of IL-1 β , IL-6, IL-4, IL-10, and TNF- α [33]. Eucalyptus oil was found to improve systemic inflammation, without reducing the activities of phagocytic monocytes and macrophages [34]. Essential oils component from orange peel (*Citrus clementine*), limonene, has been shown to normalize levels of TNF- α and IL-6 in SARS-CoV-2-infected huh-7 cells [35].

A factor determining the efficacy of essential oils as an adjunct therapy for COVID-19 management, other than the difference in compositions, is their administration route. Inhalation and nebulization have been used as administration methods for essential oils [16,17]. No adverse

effects were reported in these two studies. A study measured serum ferritin, C-reactive protein (CRP), and neutrophil-lymphocyte ratio (NLR) during treatment and concluded that the essential oils were safe [15]. However, a wide variety of bioactive compounds in the essential oils of interest might exert drug interactions that are unclear whether the interaction is antagonistic or synergistic.




Figure 3. Mechanisms of essential oil in blocking the entry of SARS-CoV-2 (A) and interacting with viral protein (B). Attenuation of SARS-CoV-2-induced pro-inflammatory cytokines release by essential oils (C). Reproduced under the terms of Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>), citing [19].

Conclusion

Essential oils are efficacious in managing mild COVID-19 symptoms. They may also have the potential to act as anti-SARS-CoV-2 agents. However, the limited sample size and study design limit the interpretation of the direct anti-viral effects of essential oils. The use of essential oil as a mixture, instead of using its single component, further limits the interpretation of the available evidence. We recommend further research using single essential oils such as limonene and eucalyptol to observe whether they interact synergistically or antagonistically.

Ethics approval

Not required.

Acknowledgments

None.

Competing interests

All the authors declare that there are no conflicts of interest.

Funding

This study received no external funding.

Underlying data

All data underlying the results have been presented in this article.

How to cite

Duta TF, Rizki DR, Purnama A, *et al.* Essential oils for COVID-19 management: A systematic review of randomized controlled trials. *Narra X* 2023; 1 (2): e84 - <http://doi.org/10.52225/narrax.vi12.84>.

References

1. Ciotti M, Ciccozzi M, Terrinoni A, *et al.* The COVID-19 pandemic. *Crit Rev Clin Lab Sci* 2020;57(6):365-388.
2. World Health Organization. Coronavirus (COVID-19) dashboard. Available from: <https://covid19.who.int/>. Accessed: 5 April 2023.
3. Harapan H, Itoh N, Yufika A, *et al.* Coronavirus disease 2019 (COVID-19): A literature review. *J Infect Public Health* 2020;13(5):667-673.
4. Alimohamadi Y, Sepandi M, Taghdir M, *et al.* Determine the most common clinical symptoms in COVID-19 patients: A systematic review and meta-analysis. *J Prev Med Hyg* 2020;61(3):E304.
5. Wong CK, Au IC, Lau KT, *et al.* Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA. 2 wave: A retrospective cohort study. *Lancet Infect Dis* 2022;22(12):1681-1693.
6. Burdet C, Ader F. Real-world effectiveness of oral antivirals for COVID-19. *Lancet* 2022;400(10359):1175-1176.
7. de Leon VNOM, Pilapil JAH, Fernandez DYHI, *et al.* Anti-HIV reverse transcriptase plant polyphenolic natural products with in silico inhibitory properties on seven non-structural proteins vital in SARS-CoV-2 pathogenesis. *J Genet Eng Biotechnol* 2021;19(1):104.
8. Gordon CJ, Tchesnokov EP, Feng JY, *et al.* The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. *J Biol Chem* 2020;295(15):4773-4779.
9. Ainane T. Moroccan traditional treatment for fever and influenza, similar to symptoms of coronavirus COVID-19 disease: Mini Review. *J Anal Sci Technol* 2020;2(1):2021-2023.
10. Zuzarte M, Salgueiro L. Essential oils in respiratory mycosis: A review. *Molecules* 2022;27(13):4140.
11. Ahmady S, Rezaei M, Khatony A. Comparing effects of aromatherapy with lavender essential oil and orange essential oil on fatigue of hemodialysis patients: A randomized trial. *Complement Ther Clin Pract* 2019;36:64-68.
12. Wagner L, Cramer H, Kloese P, *et al.* Herbal medicine for cough: A systematic review and meta-analysis. *Complement Med Res* 2015;22(6):359-368.
13. Ackova DG, Maksimova V, Smilkov K. Plant bioactive compounds affecting biomarkers and final outcome of COVID-19. *Arhiv za Farmaciju* 2022;72(2):212-230.
14. Alam SS, Afrin MMR, Richi S, *et al.* Traditional herbal medicines, bioactive metabolites, and plant products against COVID-19: Update on clinical trials and mechanism of actions. *Front Pharmacol* 2021;12:671498.
15. Dutt JG, Suthar B, Malek N, *et al.* A randomized and comparative study to assess safety and efficacy of supplemental treatment of a herbal formulation - Aayudh Advance comprising essential oils in patients with coronavirus 2019 (COVID-19). *Contemp Clin Trials Commun* 2021;22:100755.
16. Hawkins JH, Keenan C, Dunne L, *et al.* Aromatherapy blend of thyme, orange, clove bud, and frankincense boosts energy levels in post-COVID-19 female patients: A randomized, double-blinded, placebo controlled clinical trial. *Complement Ther Med* 2022;67:102823.
17. Rathod RM, Vijayakumar R, Soni A, *et al.* Essential oil nebulization in mild COVID-19(EONCO): Early phase exploratory clinical trial. *J Ayurveda Integr Med* 2022;13(3):100626.
18. Torres NL, Monteiro MLG, Galvan D, *et al.* An evaluation of the potential of essential oils against SARS-CoV-2 from in silico studies through the systematic review using a chemometric approach. *Pharmaceuticals* 2021;14(11):1138.

19. Iqhrammullah M, Rizki DR, Purnama A, *et al.* Antiviral molecular targets of essential oils against SARS-CoV-2: A systematic review. *Sci Pharm* 2023;91(1):15.
20. Khairiah R, Fauzi A, Mariyani M, *et al.* A eucalyptus and lemon essential oils as an alternative for symptoms management of COVID-19: A single-blinded randomized controlled trial. *Malaysian J Med Health Sci* 2022;18 Suppl 17:7-14.
21. Yamada BFAS, Fedel PHC, Turrini IL, *et al.* Aromatherapy on psycho-emotional symptoms and fatigue in nursing professionals in the COVID-19 setting. *Aquichan* 2022;22(4):e2245.
22. Mohamed NAB, Nizam S, Wan SWR, *et al.* Early viral clearance among COVID-19 patients when gargling with povidone-iodine and essential oils - a clinical trial. *Int Med J* 2020;27(6):651-654.
23. Sankhe AP, Memane NS, Gawali VP, *et al.* A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India. *Complement Ther Med* 2022;67:102824.
24. Thakar A, Goyal M, Bhinde S, *et al.* Impact of AYUSH 64 as an adjunctive to standard of care in mild COVID 19-an open-label randomized controlled pilot study. *J Ayurveda Integr Med* 2022;13(3):100587.
25. Sakalli ET, Karadağ AE, Biltekin SN, *et al.* In vitro and in silico evaluation of ACE2 and LOX inhibitory activity of eucalyptus essential oils, 1,8-cineole, and citronellal. *Nat Prod Comm* 2022;17(6):1-8.
26. Demirci F, Karadağ AE, Biltekin SN, *et al.* In vitro ACE2 and 5-LOX enzyme inhibition by menthol and three different mint essential oils. *Nat Prod Comm* 2021;16(11):1-5.
27. Demirci F, Karadağ AE, Biltekin SN, *et al.* In vitro ACE2 and 5-LOX inhibition of *Rosmarinus officinalis* L. essential oil and its major component 1,8-cineole. *Rec Nat Prod* 2022;16(2):194-199.
28. Kumar KJSV, Wang MG, Chen CS, *et al.* Geranium and lemon essential oils and their active compounds downregulate angiotensin-converting enzyme 2 (ACE2), a SARS-CoV-2 spike receptor-binding domain, in epithelial cells. *Plants* 2020;9(6):770.
29. Hoffmann M, Kleine-Weber H, Schroeder S, *et al.* SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* 2020;181(2):271-280.
30. González-Maldonado PA, Burgos-Edwards N, Flores-Giubi A, *et al.* Screening of natural products inhibitors of SARS-CoV-2 entry. *Molecules* 2022;27(5):1743.
31. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: A key role for monocytes and macrophages. *Nat Rev Immunol* 2020;20(6):355-362.
32. Hojyo S, Uchida M, Tanaka K, *et al.* How COVID-19 induces cytokine storm with high mortality. *Inflamm Regen* 2020;40(1):37.
33. Fahriani M, Ilmawan M, Fajar JK, *et al.* Persistence of long COVID symptoms in COVID-19 survivors worldwide and its potential pathogenesis-a systematic review and meta-analysis. *Narra J* 2021;1(2):e36.
34. Sadlon AE, Lamson DW. Immune-modifying and antimicrobial effects of Eucalyptus oil and simple inhalation devices. *Altern Med Rev* 2010;15(1):33-43.
35. Asaad GFA, Raey MFE, Roshdy MA, *et al.* Citrus clementine peels essential oil exhibited anti-SARS-CoV-2 and its modulatory effect against cytokine storm: Evidence from in vitro and in silico studies. *Egypt J Chem* 2022;65(10):419-427.